IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Tuesday, October 3, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

LOS ANGELES, Oct. 3, 2017 /PRNewswire/ -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action

lawsuit against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (Nasdaq: ICPT) concerning possible violations of federal securities laws between May 31, 2016 and September 20, 2017,
inclusive (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the November 27, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Intercept made materially false and/or misleading statements, and/or failed to disclose, that its lead product candidate, Ocaliva, entailed undisclosed safety risks, including death, to patients suffering from primary biliary cholangitis ("PBC"). As a result, the Company's public statements were materially false and misleading at all relevant times.On September 12, 2017, Intercept issued a letter that warned physicians against overdosing patients with Ocaliva, advising them that the drug has been connected to liver injuries and death among patients suffering from PBC.On September 21, 2017, the U.S. Food & Drug Administration issued a safety announcement entitled "FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease," warning doctors after reports of multiple deaths linked to the drug. Upon release of this information, shares of Intercept fell in value materially, which caused investors harm according to the lawsuit.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PCBrian Lundin, Esq.Telephone: 888-713-1033Facsimile: [email protected]http://lundinlawpc.com/

View original content:http://www.prnewswire.com/news-releases/important-shareholder-alert-lundin-law-pc-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-and-encourages-investors-with-losses-to-contact-the-firm-300530201.html

SOURCE Lundin Law PC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook